Danusertib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Danusertib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 3 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether Danusertib can convert its Small molecule drug profile and Aurora A x Aurora B x Aurora C x Bcr-Abl T315I biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Danusertib (query alias: Danusertib) |
|---|---|
| Modality / target | Small molecule drug; Aurora A x Aurora B x Aurora C x Bcr-Abl T315I; Aurora A inhibitors, Aurora B inhibitors, Aurora C inhibitors |
| Highest global status | Phase 2 |
| Originator | Nerviano Medical Sciences S.r.l |
| Active developers | Nerviano Medical Sciences S.r.l |
The MCP disease footprint includes Philadelphia chromosome positive chronic myelogenous leukemia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| EUCTR2006-003772-35-BE | Phase 2 | Completed | 224 | Progression Free Rate at 4 months of treatment. |
| NCT00766324 | Phase 2 | Completed | 118 | PSA response rate defined according to the recommendations from the Prostate-Specific Antigen Working Group |
| NCT00872300 | Phase 2 | Terminated | 7 | Response Rate according to International Myeloma Working Group uniform response criteria for multiple myeloma. |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Phase II study of danusertib (D) in advanced/metastatic non-small cell lung cancers (NSCLC).
Phase 2; n=56; evaluation: not stated. Reported fields: mPFS = 6.4 month
Randomized phase II study of danusertib (D) in second-line metastatic castration-resistant prostate cancer (CRPC).
Phase 2; n=43; evaluation: not stated. Reported fields: PFS = 12.29 week (95%CI, 10.71 - 17.29); PFS = 12.14 week (95%CI, 10.86 - 15.14)
Phase I study of the pan aurora kinases (AKs) inhibitor PHA-739358 administered as a 24 h infusion without/with G-CSF in a 14-day cycle in patients with advanced solid tumors
Phase 1; n=40; evaluation: not stated. Reported fields: MTD = 500 mg/m2
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Danusertib addresses Philadelphia chromosome positive chronic myelogenous leukemia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: Aurora A x Aurora B x Aurora C x Bcr-Abl T315I records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2022-03-02 | Akeso Announces Clinical Trial Collaboration with Chipscreen Biosciences to Evaluate Cadonilimab in Combination with Chiauranib for Extensive-Stage Small-Cell Lung Cancer | NDA/BLA | Financial terms not disclosed |
| 2021-05-26 | TransThera will assess the combination of TT-00420 and Roche's atezolizumab as a treatment for GI tract cancers in China. | Approved | Financial terms not disclosed |
| 2000-05-08 | Research and Early Development Agreement between Vertex Pharmaceuticals Incorporated and Novartis Pharma AG | Not disclosed | US$15.0M upfront; US$800.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 3 August 2026. Counts and status fields may change as source records update.
